Showing results (1-10 of 51) with videos related to
Sort By:
Pageof 6
Alimentary Pharmacology & Therapeutics|October 4, 2014
Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitisF Baert, N Vande Casteele, S Tops, et al.Alimentary Pharmacology & Therapeutics|August 30, 2012
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assaysN Vande Casteele, D J Buurman, M G G Sturkenboom, et al.Alimentary Pharmacology & Therapeutics|September 15, 2015
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseasesK Papamichael, T Van Stappen, V Jairath, et al.Alimentary Pharmacology & Therapeutics|November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's diseaseN Vande Casteele, B G Feagan, S Vermeire, et al.Tissue Antigens|January 23, 1999
Characterization of a new HLA-B39 allele, B*3913, in a Brazilian CaucasianR Maertens, I De Canck, M E Moraes, et al.Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie|June 27, 2006
The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as PAI-1 inhibitorsA GilsAlimentary Pharmacology & Therapeutics|March 21, 2017
The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel diseaseC H Seow, Y Leung, N Vande Casteele, et al.Alimentary Pharmacology & Therapeutics|April 18, 2018
High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitisS Kurnool, N H Nguyen, J Proudfoot, et al.Thrombosis and Haemostasis|August 26, 1998
Modulation of plasminogen activator inhibitor 1 by Triton X-100--identification of two consecutive conformational transitionsA Gils, P J DeclerckPageof 6